His main research concerns Internal medicine, Surgery, Transplantation, Gastroenterology and Bone marrow. Many of his studies involve connections with topics such as Oncology and Internal medicine. His Transplantation study combines topics from a wide range of disciplines, such as Combination chemotherapy and Immunology, Lymphoma.
His Gastroenterology research is multidisciplinary, incorporating perspectives in Methotrexate, Incidence, Cumulative incidence, Adverse effect and Leukemia. His research in Bone marrow intersects with topics in Survival rate, Complication and Disease. His Cyclophosphamide research is multidisciplinary, incorporating elements of Myeloid leukemia and Marrow transplantation.
His primary areas of study are Internal medicine, Surgery, Multiple myeloma, Transplantation and Oncology. His research on Internal medicine frequently links to adjacent areas such as Gastroenterology. William I. Bensinger works mostly in the field of Gastroenterology, limiting it down to concerns involving Methotrexate and, occasionally, Randomized controlled trial.
In his study, which falls under the umbrella issue of Surgery, Leukemia and Antibody is strongly linked to Bone marrow. William I. Bensinger combines subjects such as Neutropenia and Dexamethasone with his study of Multiple myeloma. In his research on the topic of Transplantation, Haematopoiesis, Granulocyte colony-stimulating factor, CD34 and Progenitor cell is strongly related with Immunology.
William I. Bensinger spends much of his time researching Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide. His Internal medicine study frequently draws connections between adjacent fields such as Surgery. William I. Bensinger has included themes like Gastroenterology and Tolerability in his Multiple myeloma study.
His Gastroenterology research includes themes of Survival rate and Plasma cell leukemia. His work deals with themes such as Hematopoietic stem cell transplantation, Autologous transplantation, Neutropenia and Mantle cell lymphoma, which intersect with Oncology. His Dexamethasone research is multidisciplinary, incorporating perspectives in Newly diagnosed, Adverse effect, Pharmacology and Cyclophosphamide.
William I. Bensinger mainly investigates Internal medicine, Multiple myeloma, Lenalidomide, Oncology and Pomalidomide. Within one scientific family, he focuses on topics pertaining to Surgery under Internal medicine, and may sometimes address concerns connected to Mantle cell lymphoma. His Multiple myeloma study integrates concerns from other disciplines, such as Gastroenterology, Adverse effect, Survival rate and Dexamethasone.
He has included themes like Progression-free survival, Thalidomide and Clinical trial in his Lenalidomide study. His work in Oncology addresses subjects such as Hematopoietic stem cell transplantation, which are connected to disciplines such as Transplantation Conditioning. His Pomalidomide study combines topics in areas such as Regimen and Refractory Multiple Myeloma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Rainer Storb;H. Joachim Deeg;John Whitehead;Frederick Appelbaum.
The New England Journal of Medicine (1986)
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
William I. Bensinger;Paul J. Martin;Barry Storer;Reginald Clift.
The New England Journal of Medicine (2001)
Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
Ricardo Spielberger;Patrick Stiff;William Bensinger;Teresa Gentile.
The New England Journal of Medicine (2004)
Antigen CD34+ marrow cells engraft lethally irradiated baboons.
R J Berenson;R G Andrews;W I Bensinger;D Kalamasz.
Journal of Clinical Investigation (1988)
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
WI Bensinger;CH Weaver;FR Appelbaum;S Rowley.
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti;Brent R. Logan;Stephanie J. Lee;Edmund K. Waller.
The New England Journal of Medicine (2012)
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.
C Anasetti;D Amos;P G Beatty;F R Appelbaum.
The New England Journal of Medicine (1989)
Factors that influence collection and engraftment of autologous peripheral-blood stem cells.
W Bensinger;F Appelbaum;S Rowley;R Storb.
Journal of Clinical Oncology (1995)
Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma.
RJ Berenson;WI Bensinger;RS Hill;RG Andrews.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: